Potent HCV NS3 Protease Inhibition by a Water-Soluble Phyllanthin Congener

被引:3
作者
Reddy, Uma B. [2 ]
Tandon, Himani [1 ]
Pradhan, Manoj K. [4 ]
Adhikesavan, Harikrishnan [4 ]
Srinivasan, Narayanaswamy [1 ]
Das, Saumitra [2 ,3 ]
Jayaraman, Narayanaswamy [4 ]
机构
[1] Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India
[2] Indian Inst Sci, Microbiol & Cell Biol, Bangalore 560012, Karnataka, India
[3] Natl Inst Biomed Genom, Kalyani 741251, W Bengal, India
[4] Indian Inst Sci, Dept Organ Chem, Bangalore 560012, Karnataka, India
来源
ACS OMEGA | 2020年 / 5卷 / 20期
关键词
HEPATITIS-C-VIRUS; CRYSTAL-STRUCTURES; SERINE-PROTEASE; RNA REPLICATION; AMARUS; PROTEINASE; RESISTANCE; CLEAVAGE; FITNESS; ASSAY;
D O I
10.1021/acsomega.0c00786
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
NS3/4A protease of hepatitis C virus (HCV) plays an important role in viral RNA replication. A 1,4-diphenylbutanedicarboxylic acid derivative, namely, phyllanthin, extracted from the leaf of a herbal plant, Phyllanthus amarus, inhibits HCV NS3/4A protease and replication activities. However, the reduced aqueous solubility, high toxicity, and poor oral bioavailability are major impediments with phyllanthin. We herein present a design approach to generate phyllanthin congeners in order to potentiate inhibition activity against protease. The phyllanthin congeners were synthesized by chemical methods and subjected to systematic biological studies. One of the congeners, annotated as D8, is identified as a novel and potent inhibitor of the HCV-NS3/4Aprotease activity in vitro and the viral RNA replication in cell culture. Structural analysis using the computational-based docking approach demonstrated important noncovalent interactions between D8 and the catalytic residues of the viral protease. Furthermore, D8 was found to be significantly nontoxic in cell culture. More importantly, oral administration of D8 in BALB/c mice proved its better tolerability and bioavailability, as compared to native phyllanthin. Taken together, this study reveals a promising candidate for developing anti-HCV therapeutics to control HCV-induced liver diseases.
引用
收藏
页码:11553 / 11562
页数:10
相关论文
共 50 条
  • [31] Synthetic bulky NS4A peptide variants bind to and inhibit HCV NS3 protease
    El-Araby, Moustafa E.
    Omar, Abdelsattar M.
    Soror, Sameh H.
    Arold, Stefan T.
    Khayat, Maan T.
    Asfour, Hani Z.
    Bamane, Faida
    Elfaky, Mahmoud A.
    JOURNAL OF ADVANCED RESEARCH, 2020, 24 : 251 - 259
  • [32] Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors
    Vendeville, Sandrine
    Nilsson, Magnus
    de Kock, Herman
    Lin, Tse-I
    Antonov, Dmitry
    Classon, Bjorn
    Ayesa, Susana
    Ivanov, Vladimir
    Johansson, Per-Ola
    Kahnberg, Pia
    Eneroth, Anders
    Wikstrom, Kristina
    Vrang, Lotta
    Edlund, Michael
    Lindstrom, Stefan
    Van de Vreken, Wim
    McGowan, David
    Tahri, Abdellah
    Hua, Lili
    Lenz, Oliver
    Delouvroy, Frederic
    Van Dooren, Marleen
    Kindermans, Natalie
    Surleraux, Dominique
    Wigerinck, Piet
    Rosenquist, Asa
    Samuelsson, Bertil
    Simmen, Kenneth
    Raboisson, Pierre
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (23) : 6189 - 6193
  • [33] Design, Synthesis, and Evaluation of Oxygen-Containing Macrocyclic Peptidomimetics as Inhibitors of HCV NS3 Protease
    Velazquez, Francisco
    Venkatraman, Srikanth
    Blackman, Melissa
    Pinto, Patrick
    Bogen, Stephane
    Sannigrahi, Mousumi
    Chen, Kevin
    Pichardo, John
    Hart, Andrea
    Tong, Xiao
    Girijavallabhan, Viyyoor
    Njoroge, F. George
    JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (03) : 700 - 708
  • [34] Mechanistic studies of electrophilic protease inhibitors of full length hepatic C virus (HCV) NS3
    Poliakov, Anton
    Sandstrom, Anja
    Akerblom, Eva
    Danielson, U. Helena
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2007, 22 (02) : 191 - 199
  • [35] Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitors
    Franco, S.
    Bellido, R.
    Aparicio, E.
    Canete, N.
    Garcia-Retortillo, M.
    Sola, R.
    Tural, C.
    Clotet, B.
    Paredes, R.
    Martinez, M. A.
    JOURNAL OF VIRAL HEPATITIS, 2011, 18 (10) : E578 - E582
  • [36] VANIPREVIR HCV NS3/4A Protease Inhibitor Treatment of Hepatitis C
    Hammond, E.
    Lucas, A.
    Lucas, M.
    Phillips, E.
    Gaudieri, S.
    DRUGS OF THE FUTURE, 2010, 35 (10) : 803 - 813
  • [37] Preclinical characterization of the novel HCV NS3 protease inhibitor GS-9256
    Yang, Huiling
    Yang, Chris
    Wang, Yujin
    Rhodes, Gerry
    Robinson, Margaret
    Cheng, Guofeng
    Qi, Xiaoping
    Mo, Hongmei
    Tian, Yang
    Pakdaman, Rowchanak
    Sheng, X. Christopher
    Kim, Choung U.
    Delaney, William E.
    ANTIVIRAL THERAPY, 2017, 22 (05) : 413 - 420
  • [38] Activity of compounds from Taxillus sutchuenensis as inhibitors of HCV NS3 serine protease
    Yang, Liyuan
    Lin, Jun
    Zhou, Bin
    Liu, Yangang
    Zhu, Baoquan
    NATURAL PRODUCT RESEARCH, 2017, 31 (04) : 487 - 491
  • [39] Characterization of NS3 protease from an Egyptian HCV genotype 4a isolate
    Bahgat, Mahmoud Mohamed
    Ibrahim, Ahmed Atef
    Abd-Elshafy, Dina Nadeem
    Mesalam, Ahmed Atef
    Gewaid, Hossam Eid
    Ismaeil, Amany Abd-Elghany
    El-Waseef, Ahmed Mohamed
    Maghraby, Amany Sayed
    Barakat, Ahmed Barakat
    El-Far, Mohamed Abd-Elhafez
    Ghanem, Hossam El-Din Ahmed
    Mohamed, Amro Mahmoud
    Ali, Mohamed Ahmed
    ARCHIVES OF VIROLOGY, 2009, 154 (10) : 1649 - 1657
  • [40] In Silico Screening for Potent Inhibitors against the NS3/4A Protease of Hepatitis C Virus
    Meeprasert, Arthitaya
    Rungrotmongkol, Thanyada
    Li, Mai Suan
    Hannongbua, Supot
    CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (21) : 3465 - 3477